TG Therapeutics, Inc. (TGTX)

Market Cap	4.49B
Revenue (ttm)	531.90M
Net Income (ttm)	447.47M
Shares Out	146.20M
EPS (ttm)	2.78
PE Ratio	11.06
Forward PE	20.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,973,676
Open	29.54
Previous Close	29.54
Day's Range	29.09 - 32.03
52-Week Range	25.28 - 46.48
Beta	1.86
Analysts	Strong Buy
Price Target	51.60 (+68.02%)
Earnings Date	Mar 2, 2026

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 338
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Analyst Summary

According to 5 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price target is $51.6, which is an increase of 68.02% from the latest price.

Price Target

$51.6

(68.02% upside)

Analyst Consensus: Strong Buy